Cargando…
In vitro activity of antiamoebic drugs against clinical isolates of Entamoeba histolytica and Entamoeba dispar
BACKGROUND: Amoebiasis is a major public health problem in tropical and subtropical countries. Although a number of antiamoebic agents are used for its treatment, yet the susceptibility data on clinical isolates of Entamoeba histolytica and Entamoeba dispar are not available. Therefore, the present...
Autores principales: | , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2004
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC544836/ https://www.ncbi.nlm.nih.gov/pubmed/15610563 http://dx.doi.org/10.1186/1476-0711-3-27 |
_version_ | 1782122161420369920 |
---|---|
author | Bansal, Devendra Sehgal, Rakesh Chawla, Yogesh Mahajan, Ramesh Chander Malla, Nancy |
author_facet | Bansal, Devendra Sehgal, Rakesh Chawla, Yogesh Mahajan, Ramesh Chander Malla, Nancy |
author_sort | Bansal, Devendra |
collection | PubMed |
description | BACKGROUND: Amoebiasis is a major public health problem in tropical and subtropical countries. Although a number of antiamoebic agents are used for its treatment, yet the susceptibility data on clinical isolates of Entamoeba histolytica and Entamoeba dispar are not available. Therefore, the present study was aimed to assess the in vitro susceptibility of clinical isolates of E. histolytica and E. dispar to metronidazole, chloroquine, emetine and tinidazole. METHODS: A total of 45 clinical isolates (15 E. histolytica and 30 E. dispar) were maintained in polyxenic cultures followed by monoxenic cultures. In vitro drug sensitivity (IC(50)) of clinical isolates and standard reference strain of E. histolytica (HM1: IMSS) was assessed by nitro blue tetrazolium (NBT) reduction assay after exposure to various concentrations of each drug. RESULTS: The results showed that all clinical isolates had a higher IC(50 )compared to reference strain to all the four drugs. E. histolytica isolates appeared to be more susceptible [IC(50 )(μm) 13.2,26.3,31.2 and 12.4] compared to E. dispar isolates [IC(50)(μm) 15.6,28.9,32.8 and 13.2] and the reference strain of E. histolytica [IC(50 )(μm) 9.5, 15.5, 29.9 and 10.2] to the metronidazole, chloroquine, emetine and tinidazole respectively. CONCLUSIONS: The results indicate that till date, Entamoeba isolates in India do not seem to be resistant to the commonly used antiamoebic drugs. |
format | Text |
id | pubmed-544836 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2004 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-5448362005-01-21 In vitro activity of antiamoebic drugs against clinical isolates of Entamoeba histolytica and Entamoeba dispar Bansal, Devendra Sehgal, Rakesh Chawla, Yogesh Mahajan, Ramesh Chander Malla, Nancy Ann Clin Microbiol Antimicrob Research BACKGROUND: Amoebiasis is a major public health problem in tropical and subtropical countries. Although a number of antiamoebic agents are used for its treatment, yet the susceptibility data on clinical isolates of Entamoeba histolytica and Entamoeba dispar are not available. Therefore, the present study was aimed to assess the in vitro susceptibility of clinical isolates of E. histolytica and E. dispar to metronidazole, chloroquine, emetine and tinidazole. METHODS: A total of 45 clinical isolates (15 E. histolytica and 30 E. dispar) were maintained in polyxenic cultures followed by monoxenic cultures. In vitro drug sensitivity (IC(50)) of clinical isolates and standard reference strain of E. histolytica (HM1: IMSS) was assessed by nitro blue tetrazolium (NBT) reduction assay after exposure to various concentrations of each drug. RESULTS: The results showed that all clinical isolates had a higher IC(50 )compared to reference strain to all the four drugs. E. histolytica isolates appeared to be more susceptible [IC(50 )(μm) 13.2,26.3,31.2 and 12.4] compared to E. dispar isolates [IC(50)(μm) 15.6,28.9,32.8 and 13.2] and the reference strain of E. histolytica [IC(50 )(μm) 9.5, 15.5, 29.9 and 10.2] to the metronidazole, chloroquine, emetine and tinidazole respectively. CONCLUSIONS: The results indicate that till date, Entamoeba isolates in India do not seem to be resistant to the commonly used antiamoebic drugs. BioMed Central 2004-12-21 /pmc/articles/PMC544836/ /pubmed/15610563 http://dx.doi.org/10.1186/1476-0711-3-27 Text en Copyright © 2004 Bansal et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Bansal, Devendra Sehgal, Rakesh Chawla, Yogesh Mahajan, Ramesh Chander Malla, Nancy In vitro activity of antiamoebic drugs against clinical isolates of Entamoeba histolytica and Entamoeba dispar |
title | In vitro activity of antiamoebic drugs against clinical isolates of Entamoeba histolytica and Entamoeba dispar |
title_full | In vitro activity of antiamoebic drugs against clinical isolates of Entamoeba histolytica and Entamoeba dispar |
title_fullStr | In vitro activity of antiamoebic drugs against clinical isolates of Entamoeba histolytica and Entamoeba dispar |
title_full_unstemmed | In vitro activity of antiamoebic drugs against clinical isolates of Entamoeba histolytica and Entamoeba dispar |
title_short | In vitro activity of antiamoebic drugs against clinical isolates of Entamoeba histolytica and Entamoeba dispar |
title_sort | in vitro activity of antiamoebic drugs against clinical isolates of entamoeba histolytica and entamoeba dispar |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC544836/ https://www.ncbi.nlm.nih.gov/pubmed/15610563 http://dx.doi.org/10.1186/1476-0711-3-27 |
work_keys_str_mv | AT bansaldevendra invitroactivityofantiamoebicdrugsagainstclinicalisolatesofentamoebahistolyticaandentamoebadispar AT sehgalrakesh invitroactivityofantiamoebicdrugsagainstclinicalisolatesofentamoebahistolyticaandentamoebadispar AT chawlayogesh invitroactivityofantiamoebicdrugsagainstclinicalisolatesofentamoebahistolyticaandentamoebadispar AT mahajanrameshchander invitroactivityofantiamoebicdrugsagainstclinicalisolatesofentamoebahistolyticaandentamoebadispar AT mallanancy invitroactivityofantiamoebicdrugsagainstclinicalisolatesofentamoebahistolyticaandentamoebadispar |